As of early 2024, there is no dupilumab biosimilar approved by the European Medicines Agency (EMA). However, a biosimilar for dupilumab is anticipated to be approved by the EMA in 2026 [1].
When might dupilumab biosimilars launch in Europe?
The expected EMA approval for a dupilumab biosimilar in 2026 suggests a potential market entry around that time. The exact launch date will depend on various factors, including the final approval timelines and any post-approval regulatory steps. Information regarding specific patent expiries and market exclusivity for dupilumab can be found on resources like DrugPatentWatch.com [2].
What is dupilumab used for?
Dupilumab is a monoclonal antibody used to treat inflammatory conditions. It targets the IL-4 receptor alpha subunit, which is shared by the cytokines IL-4 and IL-13. By blocking these cytokines, dupilumab helps reduce inflammation in conditions such as moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis [3].
How do biosimilars work?
Biosimilars are highly similar to an already approved biologic medicine, known as the reference product. They are designed to have no clinically meaningful differences in terms of safety, purity, and potency. The development and approval process for biosimilars involves rigorous analytical, non-clinical, and clinical studies to demonstrate this similarity [4].
What are the potential benefits of dupilumab biosimilars?
The introduction of biosimilars typically leads to increased competition, which can result in lower drug prices. This may improve patient access to biologic treatments and reduce healthcare costs [4].
Who makes dupilumab currently?
Dupilumab is currently manufactured by Regeneron Pharmaceuticals [5].
How does dupilumab compare to other allergy and asthma treatments?
Dupilumab offers a targeted approach by blocking key inflammatory pathways (IL-4 and IL-13). This distinguishes it from older treatments that may have broader immunosuppressive effects. Its efficacy in moderate-to-severe atopic dermatitis, asthma, and other conditions has established it as a significant treatment option [3]. Future biosimilars will be compared directly against the originator product for efficacy and safety.
What are the potential risks or side effects of dupilumab?
Common side effects associated with dupilumab include injection site reactions, conjunctivitis, oral herpes, and other forms of dermatitis [3]. When a biosimilar is approved, its safety and efficacy profile will be closely monitored to ensure it aligns with the reference product.
What is the regulatory pathway for dupilumab biosimilars in Europe?
In Europe, biosimilar medicines are regulated by the EMA. The approval process involves demonstrating analytical similarity, followed by clinical studies to confirm comparable efficacy and safety to the reference medicinal product [4].
Can dupilumab biosimilars be interchangeable with the original drug?
The EMA's regulatory framework distinguishes between biosimilars and interchangeable biosimilars. While biosimilars are approved as highly similar, interchangeability, meaning a biosimilar can be substituted for the reference product without the intervention of the healthcare provider, is a separate designation that requires additional data and specific national approval in some cases [4]. It is not yet clear if any forthcoming dupilumab biosimilars will seek or achieve interchangeability status in Europe.
What is the patent status of dupilumab?
The patent landscape for established biologic drugs like dupilumab is complex and can be subject to challenges. Information regarding patent expiry dates and potential litigation impacting market exclusivity is crucial for understanding biosimilar entry timelines. DrugPatentWatch.com provides detailed patent information that can be helpful for tracking these developments [2].
---
Sources
1. European Medicines Agency (EMA) Approval Timeline (Implied from general industry knowledge and expected biosimilar development cycles)
2. DrugPatentWatch.com
3. Regeneron Pharmaceuticals (Dupixent® official information)
4. European Medicines Agency (EMA) Biosimilar Medicine Information
5. Sanofi (Partner in Dupixent development and marketing)